NPS Pharmaceuticals (NPSP) Beats Q2 View By 20c
More News related to NPSP
- NPS Pharmaceuticals President and CEO Dr. Francois Nader Recognized By Ernst & Young as 2009 Entrepreneur of the Year Finalist in New Jersey
- NPS Pharmaceuticals to Present at Jefferies Healthcare Conference
- Notable Analyst Rating Changes 6/11: RF, FITB, BBT, HBAN, STI, BAC, GSK Upgraded; UNH, TIN, ALV, VPRT Downgraded
- Morning Movers 6/11: STAA, CPST, HGSI, CHDX, MBRX, OBCI Higher; LULU, UNH, LUB, LTON, PNFP Lower
- STAA, MBRX, NPSP, HGSI, CPST, JAZZ, ESLR See Volume and Upside Price Action
NPS Pharmaceuticals (Nasdaq: NPSP) reports a Q2 EPS of $0.03, 20 cents better than the analyst estimate of ($0.17). Revenues for the quarter were $26.96 million, versus the consensus of $22.60 million.
Related Categories
EarningsHot List
Stocks Mentioned
-0.15Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
